Abstract:

CS therapy is widely used in the treatment of Multiple Sclerosis (MS) and spinal cord injury. However, several reports have raised serious concerns regarding the adverse neurological consequences of CS use, including significantly delaying the production of new myelin (re-myelination) around axons in adult animal models following induction of experimental myelin loss (demyelination) in the central nervous system (CNS). Dr. Divya M. Chari from Keele University School of Medicine firstly elucidate the specific mechanisms underlying the adverse consequences of CS use, then points out the biological role of myelin and process of myelin genesis, lastly she demonstrates the future directions for CS therapy in myelin genesis, and considers information gained from such research can aid in the identification of factors underpinning remyelination failure and hence nerve fibre damage and repair. It can also assist in the identification of pharmacological targets to promote effective myelination for axon preservation, in turn leading to the development of better classes of therapeutic agents or to refinements to existing treatment regimens in neurological practice.